193 related articles for article (PubMed ID: 23160320)
41. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Langer CJ; Mok T; Postmus PE
Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
[TBL] [Abstract][Full Text] [Related]
42. [Molecular targeted therapies and cytotoxics: Friends or foes?].
Vignot S; Zalcman G
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S91-2. PubMed ID: 26118883
[No Abstract] [Full Text] [Related]
43. Directed therapies in lung cancer: new hope?
Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
[TBL] [Abstract][Full Text] [Related]
44. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
45. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
46. Predicting response of molecular targeted therapies: a still possible challenge?
Labianca R; Garassino M; Torri V
Ann Oncol; 2008 May; 19(5):829-30. PubMed ID: 18296420
[No Abstract] [Full Text] [Related]
47. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
Gianni L; Grasselli G
Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
[No Abstract] [Full Text] [Related]
48. Targeting HER2 in the treatment of non-small cell lung cancer.
Mar N; Vredenburgh JJ; Wasser JS
Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
[TBL] [Abstract][Full Text] [Related]
49. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Merk J; Rolff J; Becker M; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
[TBL] [Abstract][Full Text] [Related]
50. The new drugs and biologics as sensitizers in the treatment of non-small cell lung cancer.
Turrisi AT
Suppl Tumori; 2002; 1(4):S55-7. PubMed ID: 12415822
[No Abstract] [Full Text] [Related]
51. Focus on maintenance therapy in non-small-cell lung cancer.
Tartarone A
Future Oncol; 2015; 11(2):189-92. PubMed ID: 25591835
[No Abstract] [Full Text] [Related]
52. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.
Riess JW; Neal JW
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1797-8. PubMed ID: 22005534
[No Abstract] [Full Text] [Related]
53. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
Oxnard GR
Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
[TBL] [Abstract][Full Text] [Related]
54. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
55. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacol Res; 2015 Dec; 102():90-106. PubMed ID: 26413995
[No Abstract] [Full Text] [Related]
56. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
57. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Thatcher N
Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
[TBL] [Abstract][Full Text] [Related]
58. [Treatment of lung cancer].
Ostoros G
Orv Hetil; 2010 Mar; 151(13):552-3. PubMed ID: 20304749
[No Abstract] [Full Text] [Related]
59. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
60. [Advances in combined modality therapy for patients with operable non-small cell lung cancer].
He J
Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):1-5. PubMed ID: 22490846
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
